Lei Lv

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 5

Top Topics

Replacement Therapy

Signaling Pathway

Top Venues

Cancer research

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Ruonan Zhang, Jie Wang, Yu Du, Ze Yu, Yihan Wang, Yixiao Jiang, Yixin Wu, Ting Le, Ziqi Li, Guoqiang Zhang, Lei Lv, Haijie Ma
CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma. Journal for immunotherapy of cancer 11 (11) (2023)
Xue Sun, Yue Dai, Jing He, Hongchen Li, Xuhui Yang, Wenjing Dong, Xiao Xie, Mingsong Wang, Yan-Ping Xu, Lei Lv
D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC. Oncogene (2023)
Jing He, Mingen Lin, Xinchao Zhang, Ruonan Zhang, Tongguan Tian, Yuefan Zhou, Wenjing Dong, Yajing Yang, Xue Sun, Yue Dai, Yue Xu, Zhenru Zhang, Ming Xu, Qun-Ying Lei, Yan-Ping Xu, Lei Lv
TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential. Cell discovery 9 (1) (2023)
Jing He, Mingen Lin, Xinchao Zhang, Ruonan Zhang, Tongguan Tian, Yuefan Zhou, Wenjing Dong, Yajing Yang, Xue Sun, Yue Dai, Yue Xu, Zhenru Zhang, Ming Xu, Qun-Ying Lei, Yan-Ping Xu, Lei Lv
Publisher Correction: TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential. Cell discovery 9 (1) (2023)
Xinchao Zhang, Shuyan Li, Jing He, Yunjie Jin, Ruonan Zhang, Wenjing Dong, Mingen Lin, Yajing Yang, Tongguan Tian, Yuefan Zhou, Yixin Xu, Qun-Ying Lei, Jing Zhang, Yang Zhang, Yanping Xu, Lei Lv
TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling. Cancer research 82 (11) (2022)